HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farrell, M. A. Articles by Patz, E. F. Search for Related Content PubMed PubMed Citation Articles by Farrell, M. A. Articles by Patz, E. F., Jr

Non-Small Cell Lung Cancer: FDG PET for Nodal Staging in Patients with Stage I Disease¹

¹ From the Department of Radiology (M.A.F., H.P.M., E.F.P.) and the Biometry Division, Community and Family Medicine (J.E.H.), Box 3808, Duke University Medical Center, Erwin Rd, Durham, NC 27710. Received August 16, 1999; revision requested October 14; revision received October 25; accepted November 2. Address correspondence to E.F.P. (e-mail: patz0002 @mc.duke.edu).

PURPOSE: To determine the accuracy of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in the evaluation of regional lymph nodes in patients with stage I non–small cell lung cancer (NSCLC).

MATERIALS AND METHODS: Imaging and clinical findings obtained during 5 years in 84 patients (mean age, 66 years) were reviewed. Patients had thoracic computed tomographic findings of stage I NSCLC, an FDG PET study, and histopathologic proof of lung cancer. At the time of diagnosis, disease stage was assigned on the basis of FDG PET results and was compared with the histopathologic stage to determine the accuracy of PET.

RESULTS: When PET stage was compared with histopathologic stage, the disease in 72 (86%) patients was accurately staged with PET, understaged in two (2%), and overstaged in 10 (12%). The overall sensitivity, specificity, and positive and negative predictive values for PET of regional lymph nodal metastases were 82%, 86%, 47%, and 97%, respectively.

CONCLUSION: FDG PET enables accurate staging of regional lymph node disease in patients with stage I NSCLC. A negative PET scan in these patients suggests that mediastinoscopy is unnecessary and that these patients can proceed directly to thoracotomy.

Index terms: Fluorine, radioactive • Lung, CT, 60.12111, 60.12112 • Lung, PET, 60.12163 • Lung neoplasms, 60.321 • Lung neoplasms, staging, 60.12111, 60.12112, 60.12163 • Lymphatic system, neoplasms, 67.33, 996.33 • Lymphatic system, PET, 996.12963

This article has been cited by other articles:

				Y. C. Ung, D. E. Maziak, J. A. Vanderveen, C. A. Smith, K. Gulenchyn, C. Lacchetti, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review J Natl Cancer Inst, December 5, 2007; 99(23): 1753 - 1767. [Abstract] [Full Text] [PDF]

				G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 178S - 201S. [Abstract] [Full Text] [PDF]

				F. C Detterbeck Evolution and science, progress and change Thorax, August 1, 2007; 62(8): 654 - 655. [Full Text] [PDF]

				B.-T. Kim, K. S. Lee, S. S. Shim, J. Y. Choi, O J. Kwon, H. Kim, Y. M. Shim, J. Kim, and S. Kim Stage T1 Non-Small Cell Lung Cancer: Preoperative Mediastinal Nodal Staging with Integrated FDG PET/CT--A Prospective Study Radiology, November 1, 2006; 241(2): 501 - 509. [Abstract] [Full Text] [PDF]

				S. Shiraishi, S. Tomiguchi, D. Utsunomiya, K. Kawanaka, K. Awai, S. Morishita, T. Okuda, K. Yokotsuka, and Y. Yamashita Quantitative Analysis and Effect of Attenuation Correction on Lymph Node Staging of Non-Small Cell Lung Cancer on SPECT and CT. Am. J. Roentgenol., May 1, 2006; 186(5): 1450 - 1457. [Abstract] [Full Text] [PDF]

				J. L. Port, R. S. Andrade, M. A. Levin, R. J. Korst, P. C. Lee, D. E. Becker, and N. K. Altorki Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1611 - 1615. [Abstract] [Full Text] [PDF]

				O. Birim, A. P. Kappetein, T. Stijnen, and A. J.J.C. Bogers Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer Ann. Thorac. Surg., January 1, 2005; 79(1): 375 - 382. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck, S. Falen, M. P. Rivera, J. S. Halle, and M. A. Socinski Seeking a Home for a PET, Part 2: Defining the Appropriate Place for Positron Emission Tomography Imaging in the Staging of Patients With Suspected Lung Cancer Chest, June 1, 2004; 125(6): 2300 - 2308. [Abstract] [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				G. Halter, A. K. Buck, H. Schirrmeister, I. Wurziger, F. Liewald, G. Glatting, B. Neumaier, L. Sunder-Plassmann, S. N. Reske, and M. Hetzel [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1093 - 1099. [Abstract] [Full Text] [PDF]

				D. Kahn, Y. Menda, K. Kernstine, D. Bushnell, K. McLaughlin, S. Miller, and K. Berbaum The Utility of 99mTc Depreotide Compared With F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients With Suspected Non-small Cell Lung Cancer Chest, February 1, 2004; 125(2): 494 - 501. [Abstract] [Full Text] [PDF]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				M. K. Gould, W. G. Kuschner, C. E. Rydzak, C. C. Maclean, A. N. Demas, H. Shigemitsu, J. K. Chan, and D. K. Owens Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 879 - 892. [Abstract] [Full Text] [PDF]

				D. Lardinois, A. Schallberger, D. Betticher, and H.-B. Ris Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer Ann. Thorac. Surg., April 1, 2003; 75(4): 1102 - 1106. [Abstract] [Full Text] [PDF]

				E. M. Toloza, L. Harpole, and D. C. McCrory Noninvasive Staging of Non-small Cell Lung Cancer: A Review of the Current Evidence Chest, January 1, 2003; 123(1_suppl): 137S - 146S. [Abstract] [Full Text] [PDF]

				H. Matsuguma, K. Yokoi, M. Anraku, T. Kondo, Y. Kamiyama, K. Mori, K. Tominaga, Y. Tsuura, and S. Honjo Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: A predictor of lymph node metastasis J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 278 - 284. [Abstract] [Full Text] [PDF]

				G Laking and P Price 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer Thorax, September 1, 2001; 56(90002): ii38 - 44. [Full Text] [PDF]